论文部分内容阅读
目的:探讨抗病毒药物联合黄芪注射液治疗病毒性心肌炎并发窦性心动过缓的临床疗效。方法:选取于2014年2月至2015年2月在该院接受治疗的病毒性心肌炎并发窦性心动过缓患者共114例,分为观察组和对照组。给予对照组抗病毒药物治疗,给予观察组抗病毒药物联合黄芪注射液治疗。观察治疗效果。结果:观察组痊愈率为73.7%,明显高于对照组,组间比较差异具有统计学意义(P<0.05);观察组总有效率为98.2%,明显高于对照组,组间比较差异具有统计学意义(P<0.05)。结论:抗病毒药物联合黄芪注射液治疗病毒性心肌炎并发窦性心动过缓能够具有良好的临床效果,值得推广。
Objective: To investigate the clinical efficacy of antiviral drugs combined with astragalus injection in the treatment of viral myocarditis with sinus bradycardia. Methods: A total of 114 patients with viral myocarditis complicated with sinus bradycardia admitted to our hospital from February 2014 to February 2015 were selected and divided into observation group and control group. Give the control group antiviral drug treatment, given the observation group antiviral drugs combined Astragalus injection treatment. Observe the effect of treatment. Results: The cure rate in the observation group was 73.7%, which was significantly higher than that in the control group (P <0.05). The total effective rate in the observation group was 98.2%, which was significantly higher than that in the control group Statistical significance (P <0.05). Conclusion: Antiviral drugs combined with astragalus injection in the treatment of viral myocarditis complicated with sinus bradycardia can have good clinical effect, it is worth promoting.